WASHINGTON, D.C.— Acorda Therapeutics, Inc. announced May 20 it will discontinue development of PLUMIAZ™ (diazepam) Nasal Spray, an investigational therapy which was being studied for the treatment of seizure clusters in people with epilepsy. Data from ongoing clinical trials do not demonstrate its bioequivalence to Diastat® gel, which is needed for New Drug Applications (NDA).
March 18, 2019
Study Finds Antiepileptic Drug Withdrawal Increases the Likelihood for Epileptic Seizures but Does Not Prolong Seizure Duration
Although anti-epileptic drug withdrawal increases the likelihood for epileptic seizures, it did not prolong the seizure duration, nor did it increase the rate of secondary generalization in this study.
March 13, 2019
Detecting Subtle Epileptogenic Lesions in MRI-Negative Pediatric Epilepsy
Children with drug-resistant focal epilepsy and focal cortical dysplasia who undergo complete resection of Morphometric Analysis Program (MAP)-positive regions are more likely to experience seizure-free outcomes compared with children who receive no or partial resection.